The use of tadalafil in erectile dysfunction in patients with cardiovascular disease Review article
Article Sidebar
Main Article Content
Abstract
Erectile dysfunction is a common condition that remains under-recognized and insufficiently treated. Its prevalence is increased in groups of patients with cardiovascular risk factors and cardiovascular disease. Erectile dysfunction represents an organ-specific manifestation of progressive endothelial dysfunction and reduction in blood flow through the arteries. Phosphodiesterase 5 inhibitors are effective drugs, that inhibit the pathophysiological mechanisms underlying erectile dysfunction. The safety of these drugs is evidenced in numerous studies and corroborated by years of experience with their use. Tadalafil is a well-known drug from this group, characterized by lower side effects rates, longer duration of action, and the intake timepoint regardless of meals. Considering comorbidities, treatment, and patient preferences, an effective erectile dysfunction therapy with phosphodiesterase 5 inhibitors is possible in most cases.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Haro JM, Beardsworth A, Casariego J et al. Treatment-seeking behavior of erectile dysfunction patients in Europe: Results of the Erectile Dysfunction Observational Study. J Sex Med. 2006; 3(3): 530-40.
3. Yannas D, Frizza F, Vignozzi L et al. Erectile Dysfunction Is a Hallmark of Cardiovascular Disease: Unavoidable Matter of Fact or Opportunity to Improve Men’s Health? J Clin Med. 2021; 10(10): 2221.
4. Montorsi P, Ravagnani PM, Galli S et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005; 96(12b): 19m-23m.
5. Kloner RA, Burnett AL, Miner M et al. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health. J Sex Med. 2024; 21(2): 90-116.
6. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil – review of the literature. Eur J Med Res. 2002; 7(10): 435-46.
7. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation. 2003; 108(2): 239-44.
8. Patterson D, McInnes GT, Webster J et al. Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. Br J Clin Pharmacol. 2006; 62(3): 280-7.
9. Roy S, Kloner RA, Salloum FN et al. Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. Cardiovasc Drugs Ther. 2023; 37(4): 793-806.
10. Weinsaft JW, Hickey K, Bokhari S et al. Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. Coron Artery Dis. 2006; 17(6): 493-9.
11. Bryniarski L, Rzepecki M, Klocek M et al. Bezpieczeństwo stosowania inhibitorów 5-fosfodiesterazy w leczeniu zaburzeń erekcji u pacjentów z chorobami układu krążenia. Przegl Lek. 2009; 66(4): 192-7.
12. Hsiao HL, Langenickel TH, Petruck J et al. Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension. Clin Pharmacol Ther. 2018; 103(3): 468-76.